What do systematic reviews say?

Intervention not reported

The intervention showed no clear difference in progression‐free survival1 (low certainty).

• Chemotherapy with cetuximab versus chemotherapy alone for chemotherapy‐naive advanced non‐small cell lung cancer 2014 · Cochrane Headline outcomes only
  HR 0.91 [0.83, 1]
  4 studies · 2018 participants
  Low

Intervention not reported

The intervention leads to higher one‐year survival rate2 (high certainty).

• Chemotherapy with cetuximab versus chemotherapy alone for chemotherapy‐naive advanced non‐small cell lung cancer 2014 · Cochrane Headline outcomes only
  RR 1.13 [1.02, 1.25]
  4 studies · 2018 participants
  High

Intervention not reported

The intervention may leads to higher objective response rate2 (low certainty).

• Chemotherapy with cetuximab versus chemotherapy alone for chemotherapy‐naive advanced non‐small cell lung cancer 2014 · Cochrane Headline outcomes only
  RR 1.31 [1.14, 1.51]
  4 studies · 2018 participants
  Low

Intervention not reported

• Chemotherapy with cetuximab versus chemotherapy alone for chemotherapy‐naive advanced non‐small cell lung cancer 2014 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 1801 participants
  Low

Intervention not reported

The intervention may leads to higher serious adverse events2,4 (low certainty).

• Chemotherapy with cetuximab versus chemotherapy alone for chemotherapy‐naive advanced non‐small cell lung cancer 2014 · Cochrane Headline outcomes only
  RR 37.36 [10.66, 130.95]
  1 study · 4 participants
  Low